Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
The combined safety results of two studies with the atezolizumab [...]
The combined safety results of two studies with the atezolizumab [...]
The following video interview from Practice Update discusses the promising results [...]
Results from the phase 1b COSMIC-021 study of cabozantinib in [...]
Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed [...]
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]
Interim results from the phase III IMmotion151 study to assess [...]
The following articles discuss the use of neoadjuvant therapy (drug [...]
In this interview, Dr Daniel George from the Duke Cancer Institute, Durham, [...]
Results from the IMmotion150 phase II clinical trial showed that [...]